Key Highlights
- Leverages genetic insights, microbiome analysis, and CGMs to improve GLP-1 medication outcomes.
- Comprehensive GI health screening addresses adherence and effectiveness of GLP-1 drugs.
- Personalized care with GLP-Fit™ and AI-supported nutritional guidance.
- Provides telehealth access for GLP-1 prescriptions and care with both branded and compounded drug options.
- Reduces GI issues in over 90% of patients, improving medication adherence and reducing ER visits.
Source: Business Wire
Notable Quotes
- “At Digbi Health, we leverage the gut microbiome to boost the body’s natural production of GLP-1, enabling patients to taper off medication while maintaining their health and weight loss.” — Ranjan Sinha, CEO at Digbi Health
- “While GLP-1 drugs are effective, 30% of users gain or lose less than 3% body weight. Digbi Health leverages its expertise in precision biology to improve these outcomes.” — Dr. Garima Sharma, VP of Care at Digbi Health
SoHC's Take
Digbi Health’s expansion is a significant step in integrating precision medicine with telehealth solutions. The inclusion of genetic and microbiome insights in the care process, combined with continuous glucose monitoring, sets a new standard in personalized healthcare. By addressing GI distress and ensuring access to both branded and compounded GLP-1 drugs, Digbi tackles two of the most significant pain points for both patients and employers: medication adherence and cost. This comprehensive approach not only improves patient outcomes but also reduces emergency room visits, demonstrating a clear benefit to the healthcare system.
